Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

Journal of the American College of Cardiology

Volumn 28, Issue 5, 1996, Pages 1323-1327

  Packer, Milton ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Division of Reproductive Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL;

DOSE RESPONSE; DRUG EFFICACY; DRUG USE; HEART FAILURE; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONGEVITY;

EID: 0030298330     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00301-4     Document Type: Review

References (25)

1. 1. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983;4:755-63.
2. 2. Sharpe DN, Murphy J, Coxon R, Hannan S. Enalapril in patients with chronic congestive heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984;70:271-8.
3. 3. Chalmers JP, West MJ, Cyran J, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicenter study. J Cardiovasc Pharmacol 1987;9 Suppl 3:S89-S97.
4. 4. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993: 22:1557-63.
5. 5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-35.
6. 6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
7. 7. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
8. 8. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
9. 9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
10. 10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1992;342:821-8.
11. 11. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico. GISSI-3: effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
12. 12. Massie BM, Kramer BL, Topic N. Lack of relationship between short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 1984;69:1135-41.
13. 13. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
14. 14. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study: CONSENSUS Trial). Am J Cardiol 1992;70:479-87.
15. 15. Ader R, Chatterjee K, Ports T, Brundage B, Hiramtsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by oral angiotensin-converting enzyme inhibitor. Circulation 1980;61:931-7.
16. 16. DiCarlo L, Chatterjee K, Parmely WW, et al. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol 1983;2:865-71.
17. 17. Sharpe DN, Douglas JE, Coxon RJ, Long B. Low dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet 1980;2:1154-7.
18. 18. Uretsky BF, Shaver JA, Liang C-S, et al. Modulation of hemodynamic effects with converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observation on long-term clinical, functional and biochemical responses. Am Heart J 1988;116:480-8.
19. 19. Pacher R, Globits S, Bergler-Klein J, et al. Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J 1993;14:273-8.
20. 20. Riegger GAJ. Effects of quinapril on exercise tolerance testing in patients with mild to moderate congestive heart failure. Eur Heart J 1991;12:705-11.
21. 21. Vagelos R, Nejedly M, Willson K, Yee YG, Fowler M. Comparison of low versus high dose enalapril therapy for patients with severe congestive heart failure [abstract]. J Am Coll Cardiol 1991;17:275A.
22. 22. Pacher R, Stanek B, Berger R, et al. Low versus high dose enalapril in severe heart failure [abstract]. Eur Heart J 1995;16:152.
23. 23. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat: role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-67.
24. 24. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
25. 25. Packer M. The placebo effect in heart failure. Am Heart J 1990;120:1579-82.